[To evaluate the clinicopathologic characteristics and outcome of tumor cells spreading through air spaces in patients with adenocarcinoma of lung].
[To evaluate the clinicopathologic characteristics and outcome of tumor cells spreading through air spaces in patients with adenocarcinoma of lung].
复制标题
DOI：
10.3760/cma.j.issn.0529-5807.2017.05.004
复制
发表时间：
2017-05-08
期刊：
影响因子：
--
通讯作者：
Gao, H W
中科院分区：
文献类型：
--
作者：
Sun, P L;Liu, J N;Gao, H W
目的：探讨肺腺癌气隙播散（STAS）的临床病理特征、分子生物学特征及预后。方法：收集288例有完整临床病理资料和随访资料的肺腺癌患者。将患者分为STAS阳性组（178例）和阴性组（110例），采用扩增难治性突变系统（ARMS）检测EGFR和KRAS基因突变，采用荧光原位杂交法检测ALK和ROS 1基因融合。分析STAS与临床病理、分子特征和患者预后的关系。结果：61.8%（178/288）的肺腺癌存在STAS。肿瘤直径> 3cm者STAS阳性率显著高于肿瘤直径≤ 3cm者（P=0.009），且肿瘤侵犯胸膜者STAS阳性率显著高于肿瘤直径≤ 3cm者（P
Objective: To investigate the clinicopathologic features, molecular characteristics and prognosis of spread through air space (STAS) in patients with adenocarcinoma of the lung. Methods: Two hundred and eighty-eight lung adenocarcinoma patients with complete clinicopathologic and follow-up data were included. The patients were divided into STAS positive (178 cases) and negative (110 cases) groups.EGFR and KRAS gene mutations were detected by amplification refractory mutation system (ARMS), and ALK and ROS1 gene fusion were detected by fluorescence in situ hybridization method. The relationship between STAS and clinicopathologic, molecular features, and patient outcome was analyzed. Results: STAS was present in 61.8%(178/288) of lung adenocarcinomas. The positive rate of STAS in tumors >3 cm was significantly higher than that in tumors ≤3 cm (P=0.009), and was significantly higher in tumors with pleural invasion (P